Pediatric anesthesia & critical care

Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial

Anesth AnalgPublished Randomised controlled trial

Primary result · Any perioperative respiratory adverse eventResult — go to the resultAverage RR across components 0.35 95% CI 0.20–0.60

Authors' conclusion

In preschool children undergoing tonsillectomy, the preoperative application of a tulobuterol patch could decrease the occurrence of perioperative respiratory adverse events.

Study context

Population
Pediatric patients undergoing tonsillectomy88 and 94 analysed
Participants
188 patients
Comparison
Tulobuterol patch vs placebo, applied 8 to 10 hours before surgery
  • Tulobuteroln = 88
  • Placebon = 94reference
Primary endpoint
Any perioperative respiratory adverse event: oxygen desaturation <95%, airway obstruction, laryngospasm, bronchospasm, severe coughing, or stridor (average relative effect test across components)
Methodological detailstriple-blinded (patient, anesthesia provider, and outcome assessor), placebo-controlled
  • Triple-blinded (patient, anesthesia provider, and outcome assessor)
  • Placebo-controlled

Primary result

Any perioperative respiratory adverse event

Average RR across components

0.35

95% CI 0.20–0.60

P < 0.001

Events by treatment group

Tulobuterol vs Placebo
average RR across components 0.35 (95% CI 0.20–0.60); P < 0.001

As reported in the abstract

Further findings

OutcomeTulobuterolPlaceboRR (95% CI)P value
Airway obstruction9.0%34.0%0.31 (0.17–0.56)P < 0.001
Severe coughing1.1%8.5%0.15 (0.03–0.68)P = 0.014

Original publication

Effect of Tulobuterol Patch Versus Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: A Randomized Controlled Trial. Anesth Analg. Published 19 May 2023. doi:10.1213/ane.0000000000006355

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.